SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO.(688212) 浙商证券·2025-04-23 08:35Investment Rating - The investment rating for the company is "Accumulate" [5] Core Views - The company's revenue for 2024 is projected to be 750 million yuan, representing a year-on-year growth of 10.54%, while the net profit attributable to the parent company is expected to decline by 63.68% to 21 million yuan [1][4] - In Q4 2024, the revenue is 249 million yuan, showing a slight year-on-year decrease of 0.2%, and the net profit is -16 million yuan [1][2] - For Q1 2025, the revenue is anticipated to drop by 26.9% to 124 million yuan, with a net profit of -29 million yuan [1][2] Revenue and Growth Outlook - The company is expected to face revenue pressure in the first half of 2025 due to inventory adjustments and a slowdown in hospital bidding [2] - New product commercialization is ongoing, with the introduction of electronic endoscopes, which may drive additional revenue [2] - Revenue forecasts for 2025-2027 are 827 million, 1.046 billion, and 1.317 billion yuan, with respective year-on-year growth rates of 10.32%, 26.44%, and 25.95% [4][5] Profitability Analysis - The gross profit margin for 2024 is 68.1%, down 5.7 percentage points year-on-year, leading to a net profit margin of 2.7%, a decrease of 6.3 percentage points [3] - In Q1 2025, the gross profit margin is projected to be 66.36%, with a net profit margin of -23.28% due to revenue pressures and ongoing expenses [3] - Despite short-term profit pressures, there is an expectation for gradual improvement in net profit margins post-2025 [3] Financial Summary - The company’s financial projections indicate a significant recovery in net profit from 38 million yuan in 2025 to 207 million yuan in 2027, with corresponding EPS increasing from 0.28 yuan to 1.54 yuan [4][5] - The price-to-sales ratio for 2025 is estimated at 7 times [4]